EVIDENCE IN BRIEF
although patients with higher ECOG performance status were eligible for these studies, the majority of patients (~86%) had an ECOG performance status <1. pERC also noted that approximately two-thirds of patients in both studies had prior experience with hydroxyurea, a common treatment for myelofibrosis.
Download EVIDENCE IN BRIEF
Information
Domain:
Source:
Link to this page:
Documents from same domain
Issues in Emerging Health Technologies - CADTH.ca
www.cadth.caThe Canadian Agency for Drugs and Technologies in Health (CADTH) is funded by Canadian federal, provincial and territorial governments. (www.cadth.ca)
TITLE: Follow up for Smoking Cessation Interventions ...
www.cadth.caFollow Up for Smoking Cessation Interventions 4 APPENDIX – FURTHER INFORMATION: Systematic reviews 3. Stead LF, Bergson G, Lancaster T. Physician advice for smoking cessation.
TITLE: Timely Access to Primary Care for Patients with ...
www.cadth.caTimely access to Primary Care for Patients with Chronic Diseases 5 Summary of Critical Appraisal Critical appraisal of the included observational studies is summarized below and details are available in Appendix 3, Tables A2. Observational studies
TITLE Traditional Aboriginal Pain Management Practices ...
www.cadth.caTraditional Aboriginal Pain Management Practices 4 9. Aboriginal healing in Canada: studies in therapeutic meaning and practice [Internet].
Prevention of Dehydration in Elderly Long-Term Care ...
www.cadth.caFour evidence-based guidelines were identified regarding . the prevention or identification of dehydration in geriatric patients in long-term care .
An Overview of Post–COVID-19 Condition (Long COVID)
www.cadth.caCADTH Horizon Scan An Overview of Post–COVID-19 Condition (Long COVID) 7 • what is known about post–COVID-19 condition • what the major emerging research questions being explored are • what the important implications could be for health systems to consider.
What Are Bioavailability and Bioequivalence
www.cadth.caAdvisory Committee on Bioavailability and Bioequivalence, Health Canada Although bioequivalence is most commonly discussed in relation to generic drugs, it is important to note that bioequivalence studies are also performed for brand name drugs in some situations such as: • between early and late clinical trial formulations or between the
Clinical Laboratory Costing - CADTH.ca
www.cadth.caCarleton Place Renfrew Victoria McConnell (Cornwall) St. Francis (Barry's Bay) Qu nsw ay-C rl to Eastern Counties North Lanark / North Grenville Ottawa Centre Ottawa East Ottawa West Renfrew County N Y St. Vincent Bruyère CHEO Montfort Civic (TOH/HO) Général (TOH/HO) Royal Ottawa Riverside (TOH/HO) ... environmental scan provide a ...
CEDAC FINAL RECOMMENDATION and REASONS for ... - …
www.cadth.cain the Dermatology Life Quality Index (DLQI) or a significant reduction in BSA involved, with consideration of important regions such as the face, hands, feet or genital region. Ongoing coverage for . Common Drug Review CEDAC Meeting – September 17, 2008 Page 2 of 3
Related documents
Proleukin (aldesleukin) injection label
www.accessdata.fda.govEligible patients had an Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 or 1 and normal organ function as determined by cardiac stress test, pulmonary function tests, and creatinine ≤1.5 mg/dL. Studies excluded patients with brain metastases, active infections, organ allografts and diseases requiring steroid treatment.
ECOG のPerformance Status PS）の日本語訳
www.jcog.jp付表：Performance Status ECOG のPerformance Status（PS）の日本語訳 Performance Status Score ...
Appendix III Criteria for Coverage of Exception Status Drugs
novascotia.calung and with an ECOG performance status 0 or 1. *ALECTINIB (Alecensaro 150mg Capsule) • For the first line treatment of patients with locally advanced or metastatic anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer (NSCLC).
Karnofsky/Lansky Performance Status
www.cibmtr.orgJan 31, 2009 · Karnofsky/Lansky Performance Score vs. ECOG performance score: Some transplant centers may prefer to collect and use the ECOG performance score as opposed to the Karnofsky/Lansky score. Although the ECOG and Karnofsky/Lansky performance score systems are based on similar principles, the scales are not the same. For centers that collect only the ...
Escalas de estado funcional (o performance status en cáncer
gastrolat.org(Karnofsky Performance Status scale; KPS scale o escala KPS) y la escala ECOG (Eastern Cooperative Oncology Group). Además de estas 2 escalas que se utilizan para los pacientes con cáncer, se ha desarro-llado la Escala Paliativa de Funcionalidad (Palliative Performance Scale; PPS o escala PPS), la que está
WHO performance status: Lansky/Karnofsky conversion table
kankerregister.orgThe ‘WHO score at diagnosis’ is the performance status of the patient at the moment of diagnosis (synonyms: ECOG/Zubrod score). Although this score is important for all outcome-based analyses (e.g. quality indicators), it is often not determined or registered. In addition, it can be difficult to assign a WHO performance score to children.
COMMONLY USED ABBREVIATIONS AND TERMS in …
tracs.unc.eduECOG . Eastern Cooperative Oncology Group (Used to determine Performance Status ) EDC . Electronic Data Capture : EMEA . European Agency for the Evaluation of Medicinal Products : FDA . Food and Drug Administration : FWA number . Federal Wide Assurance number (number assigned to IRB )
National Cancer Drugs Fund List - NHS England
www.england.nhs.uk7. The patient has an ECOG performance status (PS) of 0, 1 or 2. Note: treatment of patients of performance status 2 should only proceed with caution as there is limited safety data on PS 2 patients with urothelial cancer treated with atezolizumab. 8. The patient is ineligible for platinum-based chemotherapy, due to one or more of the following: